eligibility_summary
Eligibility: 14-70, relapsed/refractory CD19+ B-ALL (incl Ph+ after ≥2 TKIs) or B-cell NHL (DLBCL, PMBCL, TFL, MCL, high-grade, CLL/SLL) after standard therapy/HSCT, ALL marrow ≥5% blasts, ECOG ≤2, life expectancy ≥12 wks, adequate veins, counts/organ function, EF ≥45%, O2 >92%, contraception. Exclude: active CNS disease, uncontrolled infection (HBV/HCV/HIV/syphilis), significant heart/autoimmune/GVHD≥2, indwelling drains, pregnancy, other malignancy, prior CD19 therapy/CAR-T, recent chemo/immuno/radiation/growth factors.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Anti-CD19 CAR‑T cells (autologous, gene‑modified T‑cell therapy) given after lymphodepleting fludarabine (antimetabolite, purine analog) and cyclophosphamide (alkylating agent). Mechanisms: CAR‑T cells are engineered to recognize CD19 on B cells, triggering T‑cell activation, expansion, cytokine release, and perforin/granzyme‑mediated cytotoxicity to eliminate malignant B cells. Fludarabine/cyclophosphamide deplete host lymphocytes and immunosuppress to enhance CAR‑T engraftment and persistence. Targets: CD19+ B‑cell malignancies (ALL, DLBCL/PMBCL, transformed FL, MCL, HGBL, CLL/SLL). Key pathways/cells: CD19 B‑cell lineage antigen, T‑cell effector pathways, cytokine/CRS markers (e.g., IL‑6, CRP, ferritin) monitored.